受体相互作用蛋白2在直肠癌中的表达及临床意义

doi:10.3969/j.issn.1005-6483.2019.06.014

摘要/Abstract

摘要： 目的研究受体相互作用蛋白（RIP）2在直肠癌及癌旁组织中的表达及其与临床病理特征关系。方法直肠癌手术病人77例。使用免疫组化检测直肠癌组织及癌旁组织中RIP2的表达情况。观察以下指标：（1）RIP2在直肠癌组织和癌旁组织中的表达。（2）直肠癌组织中RIP2的表达与临床病理特征的关系。结果 77例直肠癌组织中，RIP2的阳性表达率为57.1%（44/77），癌旁组织为64.9%（50/77），两者比较，差异无统计学意义（P>0.05）。在44例直肠癌组织阳性表达的病人中，低+未分化、Ⅲ+Ⅳ期、合并淋巴结转移、脉管侵犯组的RIP2的阳性表达率高于高+中分化、Ⅰ+Ⅱ期、无淋巴结转移、无脉管侵犯组，差异有统计学意义（P<0.05），而RIP2阳性表达率与性别、年龄、肿瘤直径及有无神经侵犯无关（P>0.05）。免疫组化结果半定量分析显示，直肠癌组织中RIP2的表达较癌旁组织增加，差异有统计学意义（P<0.05）。结论 RIP2在直肠癌组织中表达增强，可能是直肠癌病人预后一个潜在判断指标。

关键词: 受体相互作用蛋白2, 直肠癌, 免疫组化

Abstract: Objective To investigate the expressions of Receptor-interacting protein 2（RIP2）in tissues of rectal cancer（RC）and adjacent tissues，and the relationship with the clinicopathologic factors of RC.Methods The clinicopathological data of 77 patients with rectal?cancer who admitted to the Renmin Hospital of Wuhan University from January 2016 to January 2017 were collected.The expressions of RIP2 in cancer and adjacent tissues were detected using immunohistochemical assay.Semi-quantitative data of immunohistochemical assay was analyzed within independent T test.The relationship between the expression of RIP2 and clinicopathologic factors was then analyzed within the chi-square test.Results In these 77 cancer cases，RIP2 is positively expressed in 44 samples，accounted for 57.1%，and 50 cases in adjacent tissues，totally accounted for 64.9%.The difference is not statistically significant（χ2 =0.983，P>0.05）.The positive expression rate of RIP2 in poorly differentiated and undifferentiated cases ，stage Ⅲ and stage Ⅳ cases，cases with lymph node metastasis and cases with vein invasion was higher than that in cases of high and middle differentiation ，stageⅠand stageⅡ，no lymph node metastasis and no vein invasion（P<0.05）.However，the positive expression of RIP2 has nothing with sex，age and tumor size（P>0.05）.Besides，semi-quantitative analysis shows that the expression of RIP1 and RIP3 in rectal cancer is less than normal tissue（t=-4.305，P<0.05）.Conclusion The expression of RIP2 in rectal cancer is up regulated，and may be a potential reference designator to judge the prognosis of patients with rectal cancer.

Key words: Receptor-interacting Protein 2, Rectal Cancer, Immunohistochemical assay

邓文宏, 易斌, 邱振东, 项明伟, 何小波, 王卫星. 受体相互作用蛋白2在直肠癌中的表达及临床意义[J]. 临床外科杂志, 2019, 27(6): 489-491.

DENG Wenhong, YI Bin, QIU Zhengdong, et al.. Expression and clinical significance of Receptor-interacting protein 2 in tissues of rectal cancer[J]. JOURNAL OF CLINICAL SURGERY, 2019, 27(6): 489-491.

参考文献

相关文章 15

[1]	郝志楠, 莫波, 闵春明, 何磊. 腹腔镜直肠癌根治术中保留左结肠动脉对肠系膜下动脉3型直肠癌病人临床疗效及术后并发症的影响[J]. 临床外科杂志, 2019, 27(6): 492-494.
[2]	罗志民, 张家驹, 赵恩宏. 全身炎性反应与直肠癌术后生存率的相关分析[J]. 临床外科杂志, 2019, 27(5): 395-398.
[3]	张明府, 吴永丰, 柳东. 腹腔镜直肠癌前切除术中保留左结肠动脉对术后吻合口漏及近期疗效的影响[J]. 临床外科杂志, 2019, 27(5): 400-403.
[4]	秦新裕, 许剑民, 任黎, 常文举. 2018版《中国结直肠癌肝转移诊断和综合治疗指南》解读[J]. 临床外科杂志, 2019, 27(1): 9-13.
[5]	饶慕圣曹胜华王学成. 肛管直肠恶性黑色素瘤一例[J]. 临床外科杂志, 2018, 26(11): 891-891.
[6]	. 中低位直肠癌新辅助治疗的个体化选择[J]. 临床外科杂志, 2018, 26(10): 733-734.
[7]	曹金鹏杨平余思李志澄朱佳成罗特东计勇. 不同微创术式治疗高龄直肠癌病人的疗效及对其免疫炎性反应及预后的影响分析[J]. 临床外科杂志, 2018, 26(10): 751-753.
[8]	任朋张烨陶建新沈仁辉王彤. 吲哚菁绿显像对减少腹腔镜结直肠癌根治术后吻合口漏的作用[J]. 临床外科杂志, 2018, 26(10): 754-756.
[9]	赵家运王志刚潘乐玉. 限制性输血对直肠癌保肛术后并发症影响分析[J]. 临床外科杂志, 2018, 26(10): 763-766.
[10]	陶俊王贵和. 局部进展期直肠癌新辅助放化疗后病理完全缓解的预测因素分析[J]. 临床外科杂志, 2018, 26(10): 756-759.
[11]	张文斌李翔. 手辅助腹腔镜在肥胖结直肠癌患者中的应用价值及疗效分析[J]. 临床外科杂志, 2018, 26(10): 760-763.
[12]	欧文权官国先. 经括约肌间切除治疗低位直肠癌保肛术的研究进展[J]. 临床外科杂志, 2018, 26(10): 797-799.
[13]	胡俊杰熊治国. 肿瘤细胞减灭术联合腹腔热灌注化疗在结直肠癌腹膜转移中的应用现状及前景[J]. 临床外科杂志, 2018, 26(10): 727-730.
[14]	王伟王代宏尹小平等. 胃癌组织IFITM1表达与临床及预后价值的探讨 [J]. 临床外科杂志, 2013, 21(5): 346-349.
[15]	沈毅涂从银何磊. 损伤控制理念在结直肠癌穿孔中的应用 [J]. 临床外科杂志, 2013, 21(5): 357-359.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed